Shares of lab services company Charles River Laboratories (NYSE:CRL) fell 5.8% in the morning session after the company reported third-quarter results that revealed significant underlying weaknesses.
Zacks Investment Research on MSN
Reasons why you should hold Charles River stock in your portfolio
Shares of Charles River CRAI have gained 7% over the past month, outperforming the industry’s 0.7% growth. The company’s ...
The life science tools company reported quarterly revenue of $1.01 billion, a 0.5% decrease year-over-year, beating the consensus estimate of $990.77 million. The impact of foreign currency ...
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced ...
Knife River (KNF) came out with quarterly earnings of $2.52 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.6 per share a year ago. These figures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback